DK1871804T3 - Antistoffer, der binder CCX-CKR2 - Google Patents

Antistoffer, der binder CCX-CKR2

Info

Publication number
DK1871804T3
DK1871804T3 DK06758551.3T DK06758551T DK1871804T3 DK 1871804 T3 DK1871804 T3 DK 1871804T3 DK 06758551 T DK06758551 T DK 06758551T DK 1871804 T3 DK1871804 T3 DK 1871804T3
Authority
DK
Denmark
Prior art keywords
ckr2
antibodies
ccx
bind
bind ccx
Prior art date
Application number
DK06758551.3T
Other languages
English (en)
Inventor
Maureen Howard
Thomas Schall
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Application granted granted Critical
Publication of DK1871804T3 publication Critical patent/DK1871804T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
DK06758551.3T 2005-04-21 2006-04-19 Antistoffer, der binder CCX-CKR2 DK1871804T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67414005P 2005-04-21 2005-04-21
PCT/US2006/015492 WO2006116319A2 (en) 2005-04-21 2006-04-19 Reagents that bind ccx-ckr2

Publications (1)

Publication Number Publication Date
DK1871804T3 true DK1871804T3 (da) 2013-12-02

Family

ID=37215373

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06758551.3T DK1871804T3 (da) 2005-04-21 2006-04-19 Antistoffer, der binder CCX-CKR2

Country Status (15)

Country Link
US (2) US7678891B2 (da)
EP (1) EP1871804B1 (da)
JP (1) JP4963701B2 (da)
KR (1) KR101289567B1 (da)
CN (1) CN101163718B (da)
AU (1) AU2006238855B2 (da)
CA (1) CA2606222C (da)
DK (1) DK1871804T3 (da)
ES (1) ES2434852T3 (da)
HK (1) HK1118558A1 (da)
IL (1) IL186509A (da)
MX (1) MX2007013108A (da)
PL (1) PL1871804T3 (da)
PT (1) PT1871804E (da)
WO (1) WO2006116319A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088895B2 (en) * 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
US9155805B2 (en) * 2009-02-20 2015-10-13 Perseus Proteomics Inc. Monoclonal antibody, and use thereof
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
JP6181040B2 (ja) 2011-03-28 2017-08-16 アブリンクス エン．ヴェー． 二特異性抗ｃｘｃｒ７免疫グロブリン単一可変ドメイン

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4927838A (en) 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors
US6537764B1 (en) 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
SE9600820D0 (sv) 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
WO1998011218A1 (en) 1996-09-10 1998-03-19 Theodor-Kocher Institute Cxcr3 chemokine receptor, antibodies, nucleic acids, and methods of use
US6140064A (en) 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
US5876946A (en) 1997-06-03 1999-03-02 Pharmacopeia, Inc. High-throughput assay
EP0897980A3 (en) 1997-08-20 2002-04-17 Smithkline Beecham Corporation CXCR4B: A human splice variant of CXCR4 chemokine receptor
CA2242308A1 (en) 1997-12-08 1999-06-08 Smithkline Beecham Laboratoires Pharmaceutiques Novel compounds
US6306653B1 (en) 1998-01-20 2001-10-23 Codon Diagnostics, Llc Detection and treatment of breast disease
EP1066310A4 (en) 1998-02-10 2002-11-27 Millennium Pharm Inc NEOKIN PROTEINS AND NUCLEIC ACIDS AND THEIR USE
NZ507161A (en) 1998-03-30 2003-12-19 Northwest Biotherapeutics Inc Theraupeutic and diagonistic applications based on the role of the CXCR-4 gene in tumorigenesis
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US6329510B1 (en) 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
US6329159B1 (en) 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
US6365356B1 (en) 1999-03-17 2002-04-02 Cornell Research Foundation, Inc. Receptors that regulate cell signaling relating to chemokines
EP1169348B1 (en) 1999-04-08 2016-02-24 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
US20020061599A1 (en) 1999-12-30 2002-05-23 Elling Christian E. Method of identifying ligands of biological target molecules
KR20030032916A (ko) 2000-02-09 2003-04-26 휴먼 게놈 사이언시즈, 인크. Ｃｃｒ5에 대한 항체
US20020064770A1 (en) 2000-03-21 2002-05-30 Nestor John J. Binding compounds and methods for identifying binding compounds
WO2002000728A2 (en) 2000-06-26 2002-01-03 Gpc Biotech Inc. Methods and compositions for isolating biologically active antibodies
US7871619B2 (en) * 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7253007B2 (en) * 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
KR101061352B1 (ko) * 2002-12-20 2011-08-31 케모센트릭스 인간 종양-발현된 ｃｃｘｃｋｒ2의 저해물질
WO2004099781A2 (en) * 2003-05-05 2004-11-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor rdc1 (rdc1)

Also Published As

Publication number Publication date
CN101163718A (zh) 2008-04-16
WO2006116319A3 (en) 2007-01-04
EP1871804A4 (en) 2010-01-06
US7678891B2 (en) 2010-03-16
IL186509A0 (en) 2008-01-20
US20100278820A1 (en) 2010-11-04
CA2606222C (en) 2015-06-23
AU2006238855B2 (en) 2011-12-22
IL186509A (en) 2012-04-30
KR101289567B1 (ko) 2013-07-24
KR20070122556A (ko) 2007-12-31
JP2008538508A (ja) 2008-10-30
HK1118558A1 (en) 2009-02-13
PT1871804E (pt) 2013-10-31
AU2006238855A1 (en) 2006-11-02
MX2007013108A (es) 2008-04-07
EP1871804B1 (en) 2013-08-28
JP4963701B2 (ja) 2012-06-27
WO2006116319A2 (en) 2006-11-02
PL1871804T3 (pl) 2014-01-31
EP1871804A2 (en) 2008-01-02
ES2434852T3 (es) 2013-12-17
CA2606222A1 (en) 2006-11-02
US20060257410A1 (en) 2006-11-16
CN101163718B (zh) 2012-10-10

Similar Documents

Publication Publication Date Title
CY2020009I1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CY2021033I1 (el) Συνθεση αντισωματος ιντερλευκινης-13
LTPA2016026I1 (lt) Anti-il-17 antikūnai
DK1888113T3 (da) Tweak-bindende antistoffer
DK1964852T3 (da) Anti-ilt7-antistof
DK2132230T3 (da) Apoptotiske anti-ige-antistoffer, der binder det membranbundne ige
DK3184546T3 (da) Antistoffer, der binder human cgrp-receptor
NL1032132A1 (nl) Nieuwe MAdCAM-antilichamen.
DK2215119T3 (da) Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme.
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
ATE380166T1 (de) Hydraulisches bindemittel
NO20071430L (no) Anti-OX4OL antistoffer
NL2002255A1 (nl) Antilichamen tegen myostatine.
BRPI0815075A2 (pt) Aglutinantes
NL1031385A1 (nl) Gesubstitueerde sulfonylaminoarylmethylcyclopropaancarbonamideverbindingen.
NL1031335A1 (nl) Gesubstitueerde N-sulfonylaminofenylethyl-2-fenoxyaceetamideverbindingen.
FR2892275B1 (fr) Poudrier.
ATA6002004A (de) Hydraulisches bindemittel
DK1871804T3 (da) Antistoffer, der binder CCX-CKR2
FI20050547A (fi) Side
BRPI0718609A2 (pt) Anticorpos modificadores de doença cancerosa.
ITPR20050013A1 (it) Trattenitore particolati.
DK1942939T4 (da) Interleukin-13-antistofsammensætning
FI20050725A0 (fi) Sideaine
FI20050927A0 (fi) Sidontalaite